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Abstract
Background: Previous studies have defined vaccinia virus (VACV)-derived T cell epitopes in
VACV-infected human leukocyte antigen-A*0201 (HLA-A2.1) transgenic (Tg) mice and A2.1-
positive human Dryvax vaccinees. A total of 14 epitopes were detected in humans and 16 epitopes
in A2.1 Tg mice; however, only two epitopes were independently reported in both systems. This
limited overlap raised questions about the suitability of using HLA Tg mice as a model system to
map human T cell responses to a complex viral pathogen. The present study was designed to
investigate this issue in more detail.
Results: Re-screening the panel of 28 A2.1-restricted epitopes in additional human vaccinees and
in A2.1 Tg mice revealed that out of the 28 identified epitopes, 13 were detectable in both systems,
corresponding to a 46% concordance rate. Interestingly, the magnitude of responses in Tg mice
against epitopes originally identified in humans is lower than for epitopes originally detected in
mice. Likewise, responses in humans against epitopes originally detected in Tg mice are of lower
magnitude.
Conclusion: These data suggest that differences in immunodominance patterns might explain the
incomplete response overlap, and that with limitations; HLA Tg mice represent a relevant and
suitable model system to study immune responses against complex pathogens.
Background
Model systems to study human responses to potential
pathogens in general, and to complex viruses such as pox-
viruses in particular, are of considerable practical interest.
They allow for characterization of immune responses
directed against epitopes potentially capable of being rec-
ognized in humans in a rigorously controlled experimen-
tal situation, without having to rely on samples derived
from exposed individuals. These issues are particularly rel-
evant in the case of pathogens of bioterrorism concern, as
well as emerging and re-emerging pathogens.
Several alternative approaches have been described to cir-
cumvent the need to use samples from infected humans.
These include using mice re-colonized with human
hematopoietic stem cells, primary in vitro restimulation
utilizing peripheral blood mononuclear cells (PBMC)
from healthy volunteers, and human leukocyte antigen
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(HLA) transgenic (Tg) mice. Murine/human chimeric sys-
tems appear to be associated with significant experimental
variability, and responses of low magnitude and diversity
compared to those observed in humans have been
reported [1]. Primary in vitro restimulation systems are an
attractive alternative, but are associated with limited
throughput, high cost, labor intensiveness, and the lack of
testing the impact of variables associated with host-path-
ogen interactions in a living organism.
Several groups have reported the development and valida-
tion of HLA Tg mice as a model system to study T cell
responses restricted by human major histocompatibility
complex (MHC) molecules [2-4]. It has been established
that HLA Tg mice represent a fairly accurate model of
human immune responses based on peptide immuniza-
tions. For example, Wenthworth and co-workers analyzed
the repertoire of influenza-specific T cell responses
obtained in HLA Tg mice with that obtained following
primary induction of human cytotoxic T lymphocyte
(CTL), and observed concordant results for approximately
85% of the peptides assayed [4].
The question of how suitable HLA Tg mice are for defining
responses to complex pathogens and antigens has, how-
ever, not been addressed in detail. This issue is relevant
because significant differences between humans and HLA
Tg mice could exist at several levels. It is possible that co-
expression of different MHC molecules might impact the
TCR repertoire, in that certain specificities are lost while
others are gained, as a function of the MHC alleles present
[5]. Differences also exist in the cellular processing
machinery operating in mice and humans at the level of
the proteasome and TAP transport [6-8]. Discrepancies
might also exist in the pattern of expression of viral anti-
gens in infected cells of human and murine origin. Fur-
thermore, it is currently unknown to what degree these
differences might influence the global outcome of
immune responses.
In our laboratory, we have characterized the T cell
response to VACV observed in infected HLA-A*0201
(A2.1) Tg mice [5] and in human Dryvax vaccinees
expressing A2.1 [9]. This enabled us to compare responses
to a complex viral pathogen in the two different systems.
We have identified a total of 28 different A2.1-restricted
epitopes, and other investigators have described three
additional epitopes (J8R11–19, A47L169–177, and B5R5–19)
using A2-positive vaccinees [10-12]. Concordant results
were found in some cases, but for the most part, epitopes
detected in humans were not detected in mice, and vice
versa. In the present study, we have further assessed the
issue of limited epitope overlap observed in humans and
HLA Tg mice.
Results and discussion
Additional testing in A2.1 Tg mice reveals a more extensive 
repertoire overlap
We previously detected 14 different epitopes utilizing
PBMC from A2.1-positive human volunteers vaccinated
with Dryvax (Figure 1A) [9]. Of these epitopes, only two
were also independently identified in VACV-infected A2.1
Tg mice [5,13-16]. Based on these results, Terajima and
Ennis hypothesized that the large number of potentially
immunogenic peptides encoded by a complex pathogen
such as VACV might explain the incomplete overlap
observed [17]. Herein, we addressed this issue in more
detail.
First, A2.1 Tg mice were inoculated with VACV and the
reactivity against each of the 28 individual A2.1-restricted
epitopes was evaluated. Responses were detected for all
epitopes previously reported in HLA Tg mice (Figure 1A;
white and grey bars). In addition, responses were detected
for 6 peptides that had been originally described in A2.1-
positive humans [9,14,18], but not reported in studies uti-
lizing Tg mice [5,15] (Figure 1A; black bars). Altogether,
responses directed against 8 of 14 (57%) epitopes
reported in humans were now also detected in A2.1 Tg
mice.
The present epitope screen differs in two experimental set-
tings from the original study by Pasquetto et al. [5]. First,
individual peptides were used here instead of peptide
pools. Second, the initial epitope identification used
splenocytes as effector cells [5], whereas the present study
utilized purified CD8+ T cells. Herein we examined the
impact of these two experimental differences. When three
representative epitopes (A14L51–59, B14R327–335, and
M1L374–383) were tested either as individual peptides or in
pools of 10 peptides, similar response magnitudes were
observed (Figure 1B). We also tested the response to the
same 3 epitopes using either purified CD8+ T cells or
splenocytes, and found that the higher non-specific inter-
feron (IFN)-γ production obtained when using spleno-
cytes led to a reduced stimulation index, and thereby
decreased sensitivity (Figure 1C).
We observed that the average responses against these
epitopes not initially identified in Tg mice were ~3 times
lower than those against the epitopes identified in the
original screen (P = 0.0098; Figure 1D). Although the 3
dominant epitopes (A14L51–59, A17L81–90, and M1L347–
383) contribute to a significant portion of the higher
response identified in mice, exclusion of these 3 epitopes
still results in a significant difference in the magnitude of
the response for the epitopes identified in humans versus
mouse (P = 0.0012). Taken together, these results suggest
that while 8 of 14 (57%) peptides reported in humans can
also be detected in A2.1 Tg mice, differences in the pat-Immunome Research 2009, 5:3 http://www.immunome-research.com/content/5/1/3
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terns of immunodominance might render them less
prominent and consequently make their detection more
difficult.
The mice utilized by Pasquetto et al. were A2.1 bxd mice
[5]. To examine whether expression of endogenous
mouse MHC molecules might also contribute to the
incomplete overlap, we tested the reactivity of the 14
epitopes identified in humans using CD8+ T cells from
VACV-infected HHD A2.1 mice, which do not express
endogenous mouse MHC [19]. However, no additional
epitopes were recognized in the HHD mice, and the
response magnitude and immunodominance pattern was
similar to that in A2.1 bxd mice (data not shown).
Testing of a broader panel of human vaccinees reveals a 
more extensive overlap
As described above, a total of 16 epitopes were initially
identified in HLA Tg mice [5,13,15]. Of these, only two
(13%) were also independently identified in human vac-
cinees (Figure 1A). Most of the candidate peptides were
tested in only 6 donors, with each individual donor yield-
Testing A2.1-restricted VACV T cell epitopes in A2.1 Tg mice using purified CD8+ T cells and individual peptides Figure 1
Testing A2.1-restricted VACV T cell epitopes in A2.1 Tg mice using purified CD8+ T cells and individual pep-
tides. (A) Splenic CD8+ cells were purified from VACV-infected A2.1 Tg mice and incubated with peptide-pulsed Jurkat-A2.1/
Kb cells, after which number of IFN-γ-producing cells was enumerated in an ELISPOT assay. Shown are the average net SFC/106 
CD8+ T cells in response to each peptide; black bars, epitopes identified by Oseroff et al. [9] in A2.1 positive donors and rec-
ognized in Tg mice upon re-screening; white bars, peptides identified by Pasquetto et al. [5] in Tg mice; grey bars, epitopes 
identified in both studies. (B) The specific T cell response to three different epitopes (B14R327–335, M1L374–383, and A14L51–59) 
was assessed 7 days after VACV infection in A2.1 Tg mice. Shown is the stimulation index for the epitopes tested either as indi-
vidual peptides (black bars) or in pools of ten peptides (white bars). (C) Shown is the stimulation index for the epitope-specific 
responses by using either CD8+ T cells (black bars) or splenocytes (white bars). (D) Shown are the average net SFC/106 CD8+ 
T cells in response to groups of epitopes recognized in Tg mice upon re-screening (black bar) and identified in Tg mice in the 
original study by Pasquetto et al. [5] (white bar). The unpaired t test with Welch's correction was used to determine if differ-
ences were significant. For all panels, average data are shown from at least two independent experiments. For each individual 
experiment samples are tested in triplicate. Error bars indicate SEM.
A
BCD
A
6
L
1
7
2
-
1
8
0
A
2
6
L
1
7
7
-
1
8
6
A
3
6
R
1
-
9
A
5
5
R
7
8
-
8
6
D
3
R
3
4
2
-
3
5
0
E
2
L
2
4
9
-
2
5
7
E
9
L
1
0
7
-
1
1
5
F
1
2
L
2
8
6
-
2
9
5
F
1
2
L
4
0
4
-
4
1
2
I
4
L
7
2
0
-
7
2
8
N
2
L
9
3
-
1
0
1
O
1
L
2
4
7
-
2
5
5
C
7
L
7
4
-
8
2
G
5
R
1
8
-
2
6
A
6
L
6
-
1
4
A
1
4
L
5
1
-
5
9
A
1
7
L
6
1
-
7
0
A
1
7
L
8
1
-
9
0
A
1
7
L
1
3
8
-
1
4
6
A
4
6
R
1
4
2
-
1
5
0
B
6
R
1
0
8
-
1
1
6
B
1
4
R
3
2
7
-
3
3
5
D
1
2
L
2
5
1
-
2
5
9
F
1
1
L
1
9
6
-
2
0
4
G
7
L
2
5
0
-
2
5
8
H
3
L
1
8
4
-
1
9
2
I
1
L
2
1
1
-
2
1
9
M
1
L
3
7
4
-
3
8
3
A
v
e
r
a
g
e
 
N
e
t
 
S
F
C
/
1
0
6
 
C
D
8
+
 
T
 
c
e
l
l
s
0
200
400
600
800
1000
1200
A14L51-59 B14R327-335 M1L374-383
Peptide
Pool
S
t
i
m
u
l
a
t
i
o
n
 
I
n
d
e
x
0
2
4
6
8
10
12
A14L51-59 B14R327-335 M1L374-383
CD8+ T cells
Splenocytes
S
t
i
m
u
l
a
t
i
o
n
 
I
n
d
e
x
0
2
4
6
8
10
12
A
v
e
r
a
g
e
 
N
e
t
 
S
F
C
/
1
0
6
 
C
D
8
+
 
T
 
c
e
l
l
s
Epitopes
identified in
re-screen
Epitopes
identified in
original screen
0
50
100
150
200
250
300
350
400
P = 0.0098Immunome Research 2009, 5:3 http://www.immunome-research.com/content/5/1/3
Page 4 of 7
(page number not for citation purposes)
ing a rather distinct pattern of epitope recognition. While
some epitopes were identified in multiple donors, most of
the epitopes were only detected in 1 out of the 6 donors
investigated [9].
To test the hypothesis that the epitopes not initially
detected in humans were associated with lower and/or
less frequent responses, we examined the responses to the
set of 16 A2.1-restricted epitopes identified in Tg mice
using PBMC from 8 different A2-positive vaccinees. The
samples tested included frozen cell aliquots from 5 of the
donors tested in the original study of Oseroff et al. [5], as
well as PBMC from 3 additional A2-positive vaccinees.
PBMC were cultured in the presence of individual pep-
tides, and the numbers of IFN-γ-producing cells were enu-
merated in an enzyme-linked immunosorbent spot
(ELISPOT) assay. The same two peptides previously iden-
tified as positive in these donors were also re-identified in
the course of the present experiments, and responses to an
additional 5 peptides originally identified in A2.1 Tg
mice, but not identified in the human donor screen of
Oseroff  et al. [9], were detected. Similar to what we
observed in the mouse experiments, responses to the
newly detected epitopes were in general lower than to
epitopes identified in the initial screen (see Additional file
1). Overall, responses directed against 7 of 16 (44%) pep-
tides initially identified in HLA Tg mice, were also
detected in humans. Considering the large donor-to-
donor variation observed, it is likely that testing of addi-
tional donors would further increase the overlap between
the two systems.
Conclusion
In summary, of the 28 epitopes identified in either
humans or mice, in this study we showed that 13 were
detected in both systems, with an overall concordance rate
of 46% (Table 1). This degree of overlap is, albeit incom-
plete, much greater than previously detected. In a similar
study, a 68% concordance rate was observed between
human immunodeficiency virus type 1 (HIV-1)-specific
CD8+ T cell epitopes recognized in both HLA-A2.1 Tg mice
and HLA-A2 HIV-1 positive patients [20]. A higher degree
of overlap was likely detected because HIV-1 epitope rec-
ognition in A2.1 Tg mice was evaluated following peptide
immunization and not natural infection, a larger cohort
of donors were tested, and HIV-1 has a significantly
smaller genome than VACV. These data suggest that while
the Tg mouse system is suitable to model immune
responses to complex pathogens, caution should be taken
in interpreting the results obtained.
Despite the more extensive and sensitive system used in
the current study, approximately one half of the epitopes
recognized specifically in one system were not recognized
in the other. Differences in TCR repertoire between mouse
and human might account for the different epitope recog-
nition. However, peptide immunizations of the human
epitopes in A2.1 Tg mice only failed in 2 of 14 instances
to generate a T cell response. This is similar to the 85%
success rate previously reported by Wentworth et al. [4],
and suggests that repertoire differences account for a rela-
tively minor percentage of the discrepancies. Differences
in the processing apparatus and antigen presentation in
murine versus human dendritic cell (DC) subsets and
other antigen-presenting cells (APCs) involved in priming
CTL immunity might also explain the differential recogni-
tion of some epitopes [7]. In mice, multiple DC subsets
have been described, however, CD8+ DCs are considered
the primary DC subset involved in directly activating
naïve CD8+ T cells during VACV infection [21]. Recently,
the CD8- DC subset has also shown to play an important
role [22]. In humans, various cell types are susceptible to
VACV infection, including dermal DCs, Langerhans cells,
and macrophages [23,24], but the primary APC responsi-
ble for naïve CD8+ T cell priming is unknown. As the pep-
tides identified in the Tg mice were effectively processed in
VACV-infected human APCs [5], differences in processing
appear an unlikely explanation. Furthermore, while mice
were immunized i.p. and humans were vaccinated by der-
mal scarification, we recently reported that either route
generates similar T cell responses, and only minor differ-
ences in magnitude of responses were observed in mice
[25].
Overall, our data suggest that while about half of the
epitopes are recognized both in humans and Tg mice, the
actual magnitudes vary, and thus differences in the immu-
nodominance pattern contribute to the degree of overlap
in the responses observed. Discrepancies in the kinetics of
viral antigen expression in infected cells of human and
murine origin might impact immunodominance [26].
Interestingly, a recent study mapping HLA-A2.1-restricted
epitopes derived from modified VACV Ankara-infected
human B cells by differential HPLC-coupled mass spec-
trometry found epitopes predominantly derived from
early gene products [27]. However, we identified A2.1-
restricted epitopes in HLA Tg mice and human vaccinees
from gene products expressed both early and late during
the viral life cycle [28]. Despite having comparable T cell
repertoires, the differences in immunodominance might
be due to distinct naïve CD8+ T cell precursor frequencies
in the two systems. We have recently demonstrated that
precursor frequencies shape the CD8+ T cell immunodom-
inance hierarchy following LCMV infection [29], and
therefore this might also apply to a more complex virus,
such as VACV. These conclusions are in agreement with
those drawn from a recent study mapping the T cell
responses in VACV-immune individuals, where it was
pointed out that an epitope might be considered immun-
odominant if recognized by both humans and HLA TgImmunome Research 2009, 5:3 http://www.immunome-research.com/content/5/1/3
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mice [30]. In summary, the present study suggests that,
with limitations, HLA Tg mice represent a relevant and
suitable model system for identification and validation of
T cell epitopes recognized during the course of complex
viral infection in humans.
Methods
Peptides
Peptides were synthesized by A and A Labs and purified to
>95% homogeneity by reverse-phase high-performance
liquid chromatography (HPLC). Purity was determined
using analytical reverse-phase HPLC and amino acid anal-
ysis, sequencing, and/or mass spectrometry. Peptides were
radio-labeled with the chloramine T method as described
[31].
Characteristics of study population
Healthy males and females between 18 and 59 years of
age were used in this study. Exclusion criteria were body
weight of < 45.4 kg and established pregnancy. Recruited
donors were vaccinated by arm scarification with a VACV
(Dryvax) vaccination as a prophylactic measure either
because of their potential exposure to VACV in a labora-
tory or hospital setting or because of their enrollment into
military and health worker vaccination program. The
blood draw was performed within 1 year of the Dryvax
vaccination. All experiments carried out with human sub-
jects were in compliance with the Helsinki Declaration.
Institutional Review Board approval (FWA# 00000032)
and appropriate informed consent were obtained for this
study.
PBMC isolation and HLA typing
PBMC were isolated from heparinized blood by gradient
centrifugation with a Histopaque-1077 (Sigma-Aldrich,
St. Louis, MO) [32], suspended in fetal bovine serum con-
taining 10% dimethyl sulfoxide, and cryo-preserved in
liquid nitrogen. Donor's PBMC were typed for HLA-A by
high-resolution polymerase chain reaction (Forensic Ana-
lytical Molecular Genetics, San Francisco, CA).
Table 1: Summary of overlap between A2.1-restricted VACV T cell epitope recognition in HLA Tg mice and human systems
Epitope Sequence Original Identification Reference Average
Net SFC/106 Cells
Tg Mice Human
A6L172–180 ILSDENYLL Human [9] - 106
A26L177–186 YLYTEYFLFL Human [9] - 164
A36R1–9 MMLVPLITV Human [9] 75 49
A55R78–86 YIYGIPLSL Human [9] - 94
D3R342–350 FLVIAINAM Human [9] - 195
E2L249–257 KIDYYIPYV Human [9] 87 192
E9L107–115 FLNISWFYI Human [9] 48 132
F12L286–295 NLFDIPLLTV Human [9] 132 252
F12L404–412 FLTSVINRV Human [9] 90 73
I4L720–728 SMHFYGWSL Human [9] - 102
N2L93–101 YVNAILYQI Human [9] - 563
O1L247–255 GLNDYLHSV Human [9] 104 77
C7L74–82 KVDDTFYYV Human + Tg mice [5,9,14,15,18] 100 178
G5R18–26 ILDDNLYKV Human + Tg mice [5,9,14] 141 271
A6L6–14 VLYDEFVTI Tg mice [5] 126 -
A14L51–59 FILGIIITV Tg mice [5] 844 60
A17L61–70 RTLLGLILFV Tg mice [5] 279 -
A17L81–90 ILMIFISSFL Tg mice [5] 773 42
A17L138–146 QIFNIISYI Tg mice [13] 231 -
A46R142–150 GLFDFVNFV Tg mice [5] 202 -
B6R108–116 LMYDIINSV Tg mice [5] 222 -
B14R327–335 HVDGKILFV Tg mice [5] 137 -
D12L251–259 RVYEALYYV Tg mice [5] 112 63
F11L196–204 FLIVSLCPT Tg mice [5] 150 -
G7L250–258 YLPEVISTI Tg mice [5] 86 -
H3L184–192 SLSAYIIRV Tg mice [5,16] 213 -
I1L211–219 RLYDYFTRV Tg mice [5] 179 115
M1L374–383 IIIPFIAYFV Tg mice [5] 840 91Immunome Research 2009, 5:3 http://www.immunome-research.com/content/5/1/3
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Mice
A2.1 Tg mice used in this study were the F 1 generation
derived from crossing homozygous Tg mice (H-2b haplo-
type) expressing a chimeric gene (A2.1/Kb) consisting of
the α1 and α2 domains of HLA and the α3 domain of H-
2Kb with BALB/c mice (The Jackson Laboratory, Bar Har-
bor, ME) [4,33,34]. The HHD A2.1 strain [19] was kindly
provided by Dr. Jack Bennink (NIAID, NIH, Bethesda,
MD). All mice were bred and maintained following NIH
guidelines and Institutional Animal Care and Use Com-
mittee-approved animal protocols (AAALAC# 000840
and OLAW# A3779-01).
Viruses and infection
The Western Reserve strain of VACV was obtained from
Dr. Bernard Moss (NIAID). Mice were infected i.p. with 2
× 106 PFU of VACV. On day 7 post-infection, the mice
were sacrificed and splenic CD8+ T cells were used in
mouse IFN-γ ELISPOT assays.
Ex vivo IFN-γ ELISPOT
IFN-γ ELISPOT assays were performed as described [5,9].
In brief, for murine assays, 2 × 105 splenic CD8+ T cells
were cultured with 105 human Jurkat cells (expressing the
same A2.1/Kb construct as in the Tg mice) pulsed with 10
μg/ml of peptide. For human assays, 2 × 105 PBMC were
incubated with 5 μg/ml of peptide. After a 20 h incubation
at 37°C, plates were developed, and responses calculated
as described [5,9,19]. Criteria for positivity were net spot-
forming cells (SFC)/106 cells ≥ 20, stimulation index ≥
2.0, and p-value ≤ 0.05 using a Student's t test in at least 2
out of 3 experiments.
Abbreviations
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cytotoxic T lymphocyte; DC: dendritic cell; ELISPOT:
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virus.
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